- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04517019
Randomised Trial Evaluating the Benefit of a Fitness Tracker Based Workout During Radiotherapy (OnkoFit II)
August 13, 2020 updated by: Dr. Cihan Gani, University Hospital Tuebingen
Randomisierte Studie Zum Nutzen Eines Fitnesstracker Basierten Aktivitätstrainings während Einer Strahlentherapeutischen Behandlung (OnkoFit II Studie)
Evaluation of the impact of an activity tracker based fitness programme on the Qualitiy of Life after oncological therapy.
Study Overview
Status
Recruiting
Conditions
Detailed Description
This monocentric, three-arm, randomized, controlled clinical trial evaluates the effect of an activity tracker based exercise program in cancer patients on the Quality of life after oncological therapy.
Quality of Life and the intensity of fatigue will be documented with the FACT-G total score of the FACIT Questionnaire six months after completion of radiotherapy.
Study Type
Interventional
Enrollment (Anticipated)
201
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Cihan Gani, MD, PD
- Phone Number: 82165 +49 (0) 7071 29
- Email: cihan.gani@med.uni-tuebingen.de
Study Contact Backup
- Name: Daniel Zips, MD, Prof.
- Phone Number: 82165 +49 (0) 7071 29
- Email: ro-info@med.uni-tuebingen.de
Study Locations
-
-
Baden-Württemberg
-
Tübingen, Baden-Württemberg, Germany, 72076
- Recruiting
- University Hospital Tübingen
-
Contact:
- Cihan Gani, MD, PD
- Phone Number: 82165 +49 (0) 7071 29
- Email: cihan.gani@med.uni-tuebingen.de
-
Contact:
- Daniel Zips, MD, Prof.
- Phone Number: 85990 +49 (0) 7071 29
- Email: ro-info@med.uni-tuebingen.de
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Capacity for consent
- Minimum age 18
- Presence of one of the following tumor diseases: Bronchial Carcinoma, Esophageal Carcinoma, Tumor of the Brain, Head and Neck Cancer, Pancreas Cancer, Sarcoma Cervix Uteri Cancer
- ECOG 0-2
- Indication for a radiotherapy or a radiochemotherapy with an intended treatment time of minimum 4 weeks (definitive/adjuvant/neoadjuvant)
Exclusion Criteria:
- Participation in any other interventional study
- Radiotherapy of Breast cancer
- Pregnancy
- Contraindication against physical activity/sport and others
- Severe cardiovascular pre-existing conditions (after myocardial infarction, apoplexy in the last 6 months, congestive heart failure NYHA > I°)
- preexisting diseases with are relevantly accompanied by a limited mobility in patients (e.g. paraparesis of the lower limbs)
- ECOG Status 3-4
- prior use of activity trackers
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Arm A (Tracker/daily step-count suggestion)
Patients receive a fitness tracker, a booklet "Physical training, exercise and cancer" and an in-person briefing on physical activity during cancer therapy.
We suggest a daily step-count which should improve the patients phyiscal activity during radiotherapy of breast cancer.
Patients receive weekly feedback and a new goal with the aim to reach a total of 6000 daily steps, which should be then maintained during radiotherapy.
|
Patients receive a fitness tracker, a booklet "Physical training, exercise and cancer" and an in-person briefing about physical activity during cancer therapy.
With offered guidelines for the daily step counts patients should improve their physical activity during radiotherapy of breast cancer.
A weekly feedback and a new goal for the next week will be provided until the individual patient reaches a daily activity of 6000 steps.
The setting will be to maintain to this daily activity of 6000 steps during radiotherapy.
|
Experimental: Arm B (Tracker/no daily step-count suggestion)
Patients receive a fitness tracker, a booklet "Physical training, exercise and cancer" and an in-person briefing on physical activity during cancer therapy. The patients self-document their daily step count during radiotherapy, there will be no recommendation for the daily count of steps. |
Patients receive a fitness tracker, a booklet "Physical training, exercise and cancer" and an in-person briefing about physical activity during cancer therapy.
With offered guidelines for the daily step counts patients should improve their physical activity during radiotherapy of breast cancer.
A weekly feedback and a new goal for the next week will be provided until the individual patient reaches a daily activity of 6000 steps.
The setting will be to maintain to this daily activity of 6000 steps during radiotherapy.
|
No Intervention: Arm C (no activity tracker)
Patients receive a booklet "Physical training, exercise and cancer" and an in-person briefing on physical activity during cancer therapy.
A fitness tracker will not be provided.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evaluation of the impact of an Activity tracker based Fitness programme on the Qualitiy of Life after oncological Therapy
Time Frame: 6 Months after completion of adjuvant radiotherapy
|
This endpoint will be evaluated by the FACT-G (Functional Assessment of Cancer Therapy - General) total scores of the FACIT (Functional Assessment of Chronic Illness Therapy) questionnaire (physical well-being values 0-28, 28 worse outcome; social/family well-being values 0-28, 28 better outcome; emotional well-being values 0-24, 24 worse outcome; functional well-being values 0-28, 28 better outcome
|
6 Months after completion of adjuvant radiotherapy
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Cihan Gani, MD, PD, University Hospital Tübingen
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
August 1, 2020
Primary Completion (Anticipated)
August 1, 2024
Study Completion (Anticipated)
August 1, 2025
Study Registration Dates
First Submitted
August 13, 2020
First Submitted That Met QC Criteria
August 13, 2020
First Posted (Actual)
August 18, 2020
Study Record Updates
Last Update Posted (Actual)
August 18, 2020
Last Update Submitted That Met QC Criteria
August 13, 2020
Last Verified
August 1, 2020
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- Respiratory Tract Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lung Diseases
- Urogenital Neoplasms
- Neoplasms by Site
- Neoplasms, Glandular and Epithelial
- Genital Neoplasms, Female
- Uterine Diseases
- Endocrine System Diseases
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Endocrine Gland Neoplasms
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Bronchial Neoplasms
- Head and Neck Neoplasms
- Esophageal Diseases
- Lung Neoplasms
- Pancreatic Diseases
- Carcinoma
- Pancreatic Neoplasms
- Esophageal Neoplasms
- Uterine Neoplasms
- Carcinoma, Bronchogenic
Other Study ID Numbers
- OnkoFit II
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Sarcoma
-
Albert Einstein College of MedicineNational Cancer Institute (NCI)TerminatedUterine Corpus Leiomyosarcoma | Stage IIA Uterine Sarcoma | Stage IIB Uterine Sarcoma | Stage IIIA Uterine Sarcoma | Stage IIIB Uterine Sarcoma | Stage IIIC Uterine Sarcoma | Stage IVA Uterine Sarcoma | Stage IVB Uterine Sarcoma | Stage IA Uterine Sarcoma | Stage IB Uterine Sarcoma | Stage IC Uterine SarcomaUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)CompletedBone Sarcoma | Retroperitoneal Sarcoma | Adult Soft Tissue SarcomaUnited States
-
Mohammed M MilhemGenentech, Inc.CompletedSarcoma | Soft Tissue Sarcoma | Metastatic Sarcoma | Locally Advanced Sarcoma | Unresectable SarcomaUnited States
-
National Cancer Institute (NCI)RecruitingMetastatic Alveolar Soft Part Sarcoma | Unresectable Alveolar Soft Part Sarcoma | Advanced Soft Tissue Sarcoma | Advanced Alveolar Soft Part SarcomaUnited States
-
National Cancer Institute (NCI)RecruitingMetastatic Leiomyosarcoma | Unresectable Leiomyosarcoma | Metastatic Sarcoma | Unresectable Soft Tissue Sarcoma | Metastatic Soft Tissue Sarcoma | Unresectable SarcomaUnited States
-
National Cancer Institute (NCI)CompletedRhabdomyosarcoma | Synovial Sarcoma | Ewing's Sarcoma | MPNST | High-risk SarcomaUnited States
-
Epizyme, Inc.RecruitingAdvanced Soft-tissue Sarcoma | Advanced Epithelioid SarcomaUnited States, Taiwan, Canada, United Kingdom
-
Brown UniversityActuate Therapeutics Inc.WithdrawnSoft Tissue Sarcoma | Osteosarcoma | Ewing Sarcoma of Bone | Leiomyosarcoma | High Grade Sarcoma | Liposarcoma | Rhabdomyosarcoma | Angiosarcoma | Bone Sarcoma | Synovial Sarcoma | Undifferentiated Pleomorphic Sarcoma | Myxofibrosarcoma | Spindle Cell SarcomaUnited States
-
David DickensWithdrawnSoft Tissue Sarcoma | Bone Sarcoma | Unresectable Soft Tissue Sarcoma | Metastatic Soft-tissue Sarcoma | Metastatic Bone Sarcoma | Unresectable Bone SarcomaUnited States
-
OHSU Knight Cancer InstituteNational Cancer Institute (NCI)WithdrawnStage III Adult Soft Tissue Sarcoma | Stage IV Adult Soft Tissue Sarcoma | Stage II Adult Soft Tissue Sarcoma | Stage IIA Adult Soft Tissue Sarcoma | Stage IIB Adult Soft Tissue Sarcoma | Stage IIC Adult Soft Tissue Sarcoma
Clinical Trials on Fitness tracker based activity training for Arm A and B. Booklet "physical training, exercise and cancer" and an introduction about physical activity during cancer therapy for Arm A, B, C
-
University Hospital TuebingenRecruiting
-
Cliniques universitaires Saint-Luc- Université...CompletedCritical IllnessBelgium
-
National Cancer Institute, NaplesUnity Health Toronto; University of CataniaActive, not recruiting
-
National Cancer Institute (NCI)Active, not recruitingAdult T Acute Lymphoblastic Leukemia | Childhood T Acute Lymphoblastic Leukemia | Ann Arbor Stage II Adult Lymphoblastic Lymphoma | Ann Arbor Stage II Childhood Lymphoblastic Lymphoma | Ann Arbor Stage III Adult Lymphoblastic Lymphoma | Ann Arbor Stage III Childhood Lymphoblastic Lymphoma | Ann... and other conditionsUnited States, Canada, Australia, New Zealand
-
National Cancer Institute (NCI)Active, not recruitingRecurrent B Acute Lymphoblastic LeukemiaUnited States, Canada, Puerto Rico, Australia, New Zealand